World Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
29(2), P. 241 - 256
Published: Jan. 5, 2023
The
coronavirus
disease
2019
(COVID-19)
pandemic
has
been
a
serious
threat
to
global
health
for
nearly
3
years.
In
addition
pulmonary
complications,
liver
injury
is
not
uncommon
in
patients
with
novel
COVID-19.
Although
the
prevalence
of
varies
widely
among
COVID-19
patients,
its
incidence
significantly
increased
severe
cases.
Hence,
there
an
urgent
need
understand
caused
by
Clinical
features
include
detectable
function
abnormalities
and
imaging
changes.
Liver
tests,
computed
tomography
scans,
ultrasound
can
help
evaluate
injury.
Risk
factors
male
sex,
preexisting
including
transplantation
chronic
disease,
diabetes,
obesity,
hypertension.
To
date,
mechanism
COVID-19-related
fully
understood.
Its
pathophysiological
basis
generally
be
explained
systemic
inflammatory
response,
hypoxic
damage,
ischemia-reperfusion
injury,
drug
side
effects.
this
review,
we
systematically
summarize
existing
literature
on
COVID-19,
clinical
features,
underlying
mechanisms,
potential
risk
factors.
Finally,
discuss
management
provide
recommendations
care
Journal of Hepatology,
Journal Year:
2021,
Volume and Issue:
75(2), P. 435 - 438
Published: April 21, 2021
Two
SARS-CoV-2
mRNA
vaccines
were
approved
to
prevent
COVID-19
infection,
with
reported
vaccine
efficacy
of
95%.
Liver
transplant
(LT)
recipients
are
at
risk
lower
immunogenicity
and
not
included
in
the
registration
trials.
We
assessed
safety
this
special
population.
Gut,
Journal Year:
2022,
Volume and Issue:
71(11), P. 2350 - 2362
Published: June 14, 2022
Knowledge
on
SARS-CoV-2
infection
and
its
resultant
COVID-19
in
liver
diseases
has
rapidly
increased
during
the
pandemic.
Hereby,
we
review
manifestations
pathophysiological
aspects
related
to
patients
without
disease
as
well
impact
of
with
chronic
(CLD),
particularly
cirrhosis
transplantation
(LT).
been
associated
overt
proinflammatory
cytokine
profile,
which
probably
contributes
substantially
observed
early
late
abnormalities.
CLD,
decompensated
cirrhosis,
should
be
regarded
a
risk
factor
for
severe
death.
LT
was
impacted
pandemic,
mainly
due
concerns
regarding
donation
recipients.
However,
did
not
represent
per
se
worse
outcome.
Even
though
scarce,
data
specific
therapy
special
populations
such
recipients
seem
promising.
vaccine-induced
immunity
seems
impaired
CLD
recipients,
advocating
revised
schedule
vaccine
administration
this
population.
American Journal of Transplantation,
Journal Year:
2021,
Volume and Issue:
21(12), P. 3919 - 3925
Published: Sept. 1, 2021
COVID-19
pandemic
dramatically
impacted
transplantation
landscape.
Scientific
societies
recommend
against
the
use
of
donors
with
active
SARS-CoV-2
infection.
Italian
Transplant
Authority
recommended
to
test
recipients/donors
for
SARS-CoV-2-RNA
immediately
before
liver
transplant
(LT)
and,
starting
from
November
2020,
grafts
deceased
infection
were
allowed
be
considered
urgent-need
candidates
active/resolved
COVID-19.
We
present
results
first
10
LTs
within
an
multicenter
series.
Only
two
recipients
had
a
positive
molecular
at
LT
and
one
them
remained
up
21
days
post-LT.
None
other
eight
was
found
during
follow-up.
IgG
in
80%
(8/10)
recipients,
71%
(5/7)
showed
neutralizing
antibodies,
expression
protective
immunity
related
recent
In
addition,
testing
RNA
on
donors'
biopsy
negative
100%
(9/9),
suggesting
very
low
risk
transmission
LT.
Immunosuppression
regimen
unchanged,
according
standard
protocol.
Despite
small
number
cases,
these
data
suggest
that
transplanting
livers
informed
immunity,
might
contribute
safely
increase
donor
pool.
Vaccines,
Journal Year:
2021,
Volume and Issue:
9(7), P. 738 - 738
Published: July 4, 2021
Vaccination
against
SARS-CoV-2
infection
is
currently
approved
and
shows
favorable
outcomes,
but
little
known
about
antibody
responses
in
solid
organ
transplant
recipients,
since
these
patients
are
to
have
an
impaired
immune
response
upon
vaccination
not
been
included
admission
studies.
We
therefore
analyzed
immunogenicity
43
liver
(LT)
recipients
a
median
of
15
days
(IQR,
12–24)
after
receiving
two
doses
the
mRNA-based
vaccine
BNT162b2
following
standard
protocol,
compared
results
control
group
consisting
20
healthcare
workers
(HCWs).
Thirty-four
(79%)
LT
developed
antibodies,
out
(100%)
(p
=
0.047).
The
IgG
titer
was
significantly
lower
(216
vs.
>2080
BAU/mL,
p
0.0001).
Age
sex
distribution
similar
that
antibodies
those
who
did
not.
Interestingly,
received
mycophenolate
mofetil
exhibited
reduced
other
(5
11
(45.5%)
29
32
(90.6%),
0.004).
In
conclusion,
our
data
reveal
group,
still
show
superior
reported
so
far.
Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
154, P. 113568 - 113568
Published: Aug. 17, 2022
Coronavirus
disease
2019
(COVID-19),
caused
by
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2),
has
become
a
global
epidemic
and
poses
major
threat
to
public
health.
In
addition
COVID-19
manifesting
as
disease,
patients
with
also
have
complications
in
extrapulmonary
organs,
including
liver
damage.
Abnormal
function
is
relatively
common
patients;
its
clinical
manifestations
can
range
from
an
asymptomatic
elevation
of
enzymes
decompensated
hepatic
function,
injury
more
prevalent
critical
patients.
Liver
comprehensive
effect
mediated
multiple
factors,
damage
directly
SARS-CoV-2,
drug-induced
damage,
hypoxia
reperfusion
dysfunction,
immune
stress
inflammatory
factor
storms.
Patients
chronic
(especially
alcohol-related
nonalcoholic
fatty
cirrhosis
hepatocellular
carcinoma)
are
at
increased
risk
death
after
infection
aggravates
disease.
This
article
reviews
the
latest
SARS-CoV-2
reports,
focusing
on
underlying
mechanism,
expounds
risk,
treatment
vaccine
safety
transplantation.
